Arch Biopartners Says Toronto's St Mike's Hospital Begins Patient Dosing In Phase II LSALT Peptide Trial

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States

Arch Biopartners to Expand Ongoing Phase 2 LSAT Peptide Trial to The US